Cognitive Function Assessment for Dementia and MCI
Dementia and Mild Cognitive Impairment: Assessment of Cognitive Functioning, Functional Autonomy, and Neuropsychiatric Symptoms.
Recruiting
Observational Study
DementiaMild Cognitive Impairment (MCI)
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
Ready to participate?
Review the details below, then apply to join this clinical trial.
At a Glance
Age
50 – 86
Sex
Any
Study type
Observational
Participants needed
151 (estimated)
Sponsor
IRCCS Centro Neurolesi Bonino Pulejo · Other
Who this trial is looking for
This trial is looking for adults aged 50 to 86 who may have dementia or mild cognitive impairment (MCI). Participants will undergo assessments to understand their cognitive abilities and daily functioning.
Are You a Good Fit for This Trial?
You may be able to join if
I am between 50 and 86 years old.
I have a suspected or confirmed diagnosis of dementia or MCI.
I am referred to the neuropsychology clinic for assessment.
I do not have severe behavioral or psychiatric disorders.
You may not be able to join if
I have a neurological disorder other than dementia or MCI.
I have unstable major psychiatric issues right now.
I have uncorrected severe vision or hearing problems.
I am taking medications that significantly affect cognition.
I have serious medical or cancer conditions that interfere with assessments.
Summarized in plain language from this trial's official eligibility criteria.
The full criteria are further down this page — only the research team can
confirm whether you qualify.
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Dementia, in its various forms, is characterized by a generalized cognitive decline that can significantly compromise personal autonomy and quality of life. Mild Cognitive Impairment (MCI), although not classified as an overt form of dementia, represents a condition at evolutionary risk and is considered a crucial transitional stage for the early detection of cognitive decline. Understanding the i…
Dementia, in its various forms, is characterized by a generalized cognitive decline that can significantly compromise personal autonomy and quality of life. Mild Cognitive Impairment (MCI), although not classified as an overt form of dementia, represents a condition at evolutionary risk and is considered a crucial transitional stage for the early detection of cognitive decline. Understanding the impact of dementia and MCI from a multidimensional perspective is now essential to fully grasp the repercussions of these conditions on patients' daily lives. The present protocol aims to investigate key aspects related to these disorders, with the objective of exploring cognitive functioning, the degree of impairment in activities of daily living, and the presence of neuropsychiatric symptoms. Through an integrated and multidisciplinary approach, the study seeks to enhance clinical management and patient care, promoting more effective, targeted, and personalized interventions.
Trial Locations
Loading…
Loading trial locations…
Facility
City
State
Country
Status
Eligibility Criteria
Inclusion Criteria:
* Age between 50 and 86 years.
* Suspected or confirmed diagnosis of dementia or mild cognitive impairment (MCI).
* Referral to the neuropsychology clinic for initial assessment or clinical monitoring.
* Absence of behavioral, psychiatric, or sensory disorders severe enough to s…
Inclusion Criteria:
* Age between 50 and 86 years.
* Suspected or confirmed diagnosis of dementia or mild cognitive impairment (MCI).
* Referral to the neuropsychology clinic for initial assessment or clinical monitoring.
* Absence of behavioral, psychiatric, or sensory disorders severe enough to significantly impair cognitive testing or completion of questionnaires.
Exclusion Criteria:
* Presence of neurological disorders other than dementia or MCI (e.g., recent stroke, severe traumatic brain injury, epilepsy, multiple sclerosis, atypical neurodegenerative diseases).
* Unstable major psychiatric comorbidities at the time of assessment (e.g., schizophrenia, bipolar disorder in active phase, untreated severe depression).
* Uncorrected severe sensory deficits (visual or auditory) affecting the validity of cognitive or functional assessments.
* Use of medications with significant cognitive impact (e.g., sedatives, high-dose antipsychotics) not stabilized at the time of evaluation.
* Presence of terminal medical or oncological conditions or other illnesses significantly interfering with the assessment procedures.
Picking one helps us show the most relevant trials first.
Your results are loading in the background — you can
change this any time from the results page.
Set your location to continue
Find My Trials uses your location to surface clinical trials near you.
Add your city or zip code to your profile and try again.